パートナーシップ

Calla Lily Clinical Careおよびその親会社は、英国政府のイノベーション関連機関であるInnovate UKから多大な支援を受けています。2021年11月、当社はInnovate UKから、研究開発の発展を目的とした追加の助成金を承認されました。

CLCC has designed an in-woman trial of our device with progesterone, working closely with the Clinical Trials Unit from University Hospitals Coventry & Warwickshire (UHCW). This is led by Professor Siobhan Quenby, our clinical co-lead and one of the world’s foremost authorities on miscarriage and preterm birth prevention. Siobhan led the highly-cited Lancet series (2021) on miscarriage and was co-applicant, major recruiter to and co-author on the two largest and most significant trials of vaginal progesterone to prevent miscarriage (PROMISE and PRISM). The results of these trials led to the UK’s NICE updating its miscarriage guideline, to now recommend women at high risk of miscarriage to take vaginal progesterone twice daily for up to 80 days – guidance that has subsequently been adopted in Australia and we believe is being closely followed in other countries, with potential to further expand the market opportunity for this indication